Andre Turenne is President and CEO of Matchpoint Therapeutics and Advisor to Atlas Venture. Prior to Matchpoint, he served as President and CEO of Voyager Therapeutics. Andre previously held a number of senior leadership roles at Sanofi, including Senior Vice President and Global Head of Business Development & Licensing, where he led or oversaw dozens of strategic transactions across therapeutic areas, modalities, and geographies. At Sanofi, he also served as General Manager for Australia and New Zealand where his team executed an award-winning product launch for multiple sclerosis and negotiated the successful, long-withheld reimbursement of a rare disease medicine. He previously served as a member of Genzyme’s executive leadership team, responsible for strategy, corporate development, and alliance management. Earlier in his career, Andre worked at life sciences consulting firm Kendall Strategies.

Andre holds an MBA from the Tuck School of Business at Dartmouth and a BA in health sciences from Kalamazoo College.